CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Instagram Outage Disrupts Thousands of U.S. Users 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
PHOENIX, Oct. 19, 2017 -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), today announced that it will release its third quarter 2017 financial results on Thursday, Nov. 2, before the U.S. financial markets open.
Following the release of the financial results, Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will host a conference call at 8:30 a.m. Eastern Daylight Time.
Investors, analysts and members of the media interested in listening to the live presentation are encouraged to join a webcast of the call available on the company’s website at https://www.insysrx.com/. Interested parties may also participate in the call by dialing (844) 263-8304 (from inside the U.S.) or (213) 358-0958 (from outside the U.S.). A webcasted replay of the conference call will be available a few hours after the event through the INVESTORS section, under the NEWS & EVENTS tab for “Presentations.”
About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets SUBSYS® (fentanyl sublingual spray), CII, and SYNDROS® (dronabinol) oral solution, CII, a proprietary, orally administered liquid formulation of dronabinol. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
SUBSYS® and SYNDROS® are trademarks of INSYS Development Company, Inc., a subsidiary of INSYS Therapeutics, Inc.
NOTE: All trademarks and registered trademarks are the property of their respective owners.
CONTACT:
Media Relations
Joe McGrath
Senior Director, Corporate Communications
INSYS Therapeutics
480-500-3101
[email protected]
Investor Relations
Jackie Marcus or Chris Hodges
Alpha IR Group
312-445-2870
[email protected]
